JP2023529216A5 - - Google Patents
Info
- Publication number
- JP2023529216A5 JP2023529216A5 JP2022575988A JP2022575988A JP2023529216A5 JP 2023529216 A5 JP2023529216 A5 JP 2023529216A5 JP 2022575988 A JP2022575988 A JP 2022575988A JP 2022575988 A JP2022575988 A JP 2022575988A JP 2023529216 A5 JP2023529216 A5 JP 2023529216A5
- Authority
- JP
- Japan
- Prior art keywords
- groups
- linear
- branched
- independently
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038276P | 2020-06-12 | 2020-06-12 | |
| US63/038,276 | 2020-06-12 | ||
| PCT/US2021/036944 WO2021252849A1 (en) | 2020-06-12 | 2021-06-11 | Inhibitors of apol1 and use of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529216A JP2023529216A (ja) | 2023-07-07 |
| JP2023529216A5 true JP2023529216A5 (https=) | 2024-06-17 |
Family
ID=76797122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575988A Pending JP2023529216A (ja) | 2020-06-12 | 2021-06-11 | Ａｐｏｌ１の阻害剤及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230014907A1 (https=) |
| EP (1) | EP4165023A1 (https=) |
| JP (1) | JP2023529216A (https=) |
| CN (1) | CN115867532A (https=) |
| AU (1) | AU2021286666A1 (https=) |
| CA (1) | CA3185144A1 (https=) |
| WO (1) | WO2021252849A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2021154997A1 (en) | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| IL296035A (en) | 2020-03-06 | 2022-10-01 | Vertex Pharma | Methods of treating apol-1 dependent focal segmental glomerulosclerosis |
| CA3185604A1 (en) | 2020-06-12 | 2021-12-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and use of the same |
| CN115867543A (zh) | 2020-06-12 | 2023-03-28 | 弗特克斯药品有限公司 | Apol1抑制剂的固体形式及其使用方法 |
| CN116547287B (zh) | 2020-08-26 | 2025-09-26 | 弗特克斯药品有限公司 | Apol1的抑制剂及其使用方法 |
| US12612379B2 (en) | 2021-11-30 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2023115167A1 (en) * | 2021-12-24 | 2023-06-29 | Psylo Pty Ltd | Compounds |
| MX2024008868A (es) | 2022-01-18 | 2024-09-23 | Maze Therapeutics Inc | Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso. |
| CN119212986A (zh) * | 2022-02-08 | 2024-12-27 | 弗特克斯药品有限公司 | 作为apol1的抑制剂的螺哌啶衍生物及其使用方法 |
| EP4476228A1 (en) * | 2022-02-08 | 2024-12-18 | Vertex Pharmaceuticals Incorporated | 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same |
| AU2023219516A1 (en) * | 2022-02-08 | 2024-08-22 | Vertex Pharmaceuticals Incorporated | 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same |
| WO2024220852A2 (en) * | 2023-04-20 | 2024-10-24 | University Of Florida Research Foundation, Incorporated | Tead core inhibitors for cancer therapeutics |
| WO2024242846A1 (en) * | 2023-05-03 | 2024-11-28 | Omniab, Inc. | Heteroarylindole inhibitors of apol-1 |
| CN116789603A (zh) * | 2023-06-06 | 2023-09-22 | 南昌大学 | 一种新型多菌灵半抗原、全抗原、抗体及其制备方法及应用 |
| WO2025042797A1 (en) * | 2023-08-18 | 2025-02-27 | Shattuck Labs, Inc. | Trim7 inhibitors and uses thereof |
| GB202401326D0 (en) * | 2024-02-01 | 2024-03-20 | Podium Bio Ltd | Novel compounds |
| WO2025231011A1 (en) * | 2024-05-01 | 2025-11-06 | Omniab, Inc. | Heteroarylindole inhibitors of apol-1 |
| WO2026012338A1 (zh) * | 2024-07-09 | 2026-01-15 | 上海旭成医药科技有限公司 | 一种APOLs抑制剂 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206382A (en) * | 1991-06-27 | 1993-04-27 | Fidia Georgetown Institute For The Neurosciences | Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders |
| EP0924209B1 (en) * | 1997-12-19 | 2003-05-02 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| GB9905010D0 (en) * | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| FR2801585B1 (fr) * | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
| GB0003397D0 (en) * | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| AU2002211828A1 (en) * | 2000-10-02 | 2002-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| FR2824827B1 (fr) * | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| FR2824826B1 (fr) * | 2001-05-17 | 2003-11-07 | Fournier Lab Sa | Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8 |
| WO2007061763A2 (en) * | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| JP5107589B2 (ja) * | 2007-02-13 | 2012-12-26 | 旭化成株式会社 | インドール誘導体 |
| DK2178870T3 (en) * | 2007-08-17 | 2018-10-22 | Lg Chemical Ltd | INDOLE AND INDAZOLIC COMPOUNDS AS AN INHIBITOR OF CELLULAR NECROSE |
| EP3186225A4 (en) * | 2014-08-27 | 2018-02-28 | The Governing Council of the University of Toronto | Cannabinoid type 1 receptor modulators |
| US11618746B2 (en) * | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
| WO2021154997A1 (en) * | 2020-01-29 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
-
2021
- 2021-06-11 CN CN202180049447.6A patent/CN115867532A/zh active Pending
- 2021-06-11 WO PCT/US2021/036944 patent/WO2021252849A1/en not_active Ceased
- 2021-06-11 CA CA3185144A patent/CA3185144A1/en active Pending
- 2021-06-11 AU AU2021286666A patent/AU2021286666A1/en not_active Abandoned
- 2021-06-11 US US17/345,256 patent/US20230014907A1/en active Pending
- 2021-06-11 EP EP21737887.6A patent/EP4165023A1/en not_active Withdrawn
- 2021-06-11 JP JP2022575988A patent/JP2023529216A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023529216A5 (https=) | ||
| JP2023530271A5 (https=) | ||
| JP2023512213A5 (https=) | ||
| JP2025505200A5 (https=) | ||
| JP4871257B2 (ja) | ２−フェニルプロピオン酸誘導体およびそれらを含有する医薬組成物 | |
| JP2022529370A5 (https=) | ||
| US6753333B2 (en) | Chiral fluoroquinolone arginine salt forms | |
| DE69010232D1 (de) | 2-(1-Piperazinyl)-4-phenylcycloalkanpyridin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten. | |
| EA017806B1 (ru) | Антимикробные соединения, их синтез и применение для лечения инфекций у млекопитающих | |
| JPH02138A (ja) | Ｌ‐ドーパ誘導体 | |
| RU2008146751A (ru) | Новые производные имидазола, их получение и использование в качестве лекартвенных средств | |
| KR101422299B1 (ko) | (2ｒ)-2-〔(4-설포닐)아미노페닐〕프로판아마이드 및 이들 화합물을 함유하는 약학 조성물 | |
| NZ190859A (en) | N-(3-phenylpropyl)-2-hydroxy-2-phenylethylamine derivatives;pharmaceutical compositions | |
| US20110257233A1 (en) | Benzoisothiazolones as inhibitors of phosphomannose isomerase | |
| EP1311506B1 (en) | Chiral fluoroquinolizinone arginine salt forms | |
| EP1080081A1 (en) | Benzofuroxan derivatives and their use in treating angina pectoris | |
| JPH07507313A (ja) | 置換ヘキサヒドロベンゾ〔α〕フェナンスリジン類 | |
| KR910004559A (ko) | 중추 신경계에 작용하는 무스카린성 약제인 4-(n-치환 아미노)-2-부티닐-1-우레아 및 티오우레아와 그의 유도체 | |
| US20050261301A1 (en) | Therapeutic ion channel blocking agents and methods of use thereof | |
| RU2007144989A (ru) | 4-фенил-5-оксо-1,4,5,6,7,8-гексагидрохинолиновые производные в качестве лекарственных средств для лечения бесплодия | |
| RU2004117548A (ru) | Амиды антраниловой кислоты и их применение в фармацевтике | |
| JP2026503618A5 (https=) | ||
| CA2123101C (en) | Nitroxyalkylamide derivative | |
| US8815847B2 (en) | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid | |
| MA27545A1 (fr) | Nouveaux dérivés de benzothiadiazines fluorées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |